Azithromycin (Zithromax, Z-Pak)
What studies of Azithromycin (Zithromax, Z-Pak) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.
1 outcome rated · see each below
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, Azithromycin (Zithromax, Z-Pak) might help some people, but research can’t show it yet. For ME/CFS, Azithromycin (Zithromax, Z-Pak) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Azithromycin (Zithromax, Z-Pak) · Long COVID is hereAzithromycin (Zithromax, Z-Pak) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Daily life and health overall
Overall symptoms1 study · 3 (few people) people took Azithromycin (Zithromax, Z-Pak) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of azithromycin (Zithromax, Z-Pak) on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- favourable clinical response
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
ME/CFS
Daily life and health overall
Overall symptoms1 study · 99 people took Azithromycin (Zithromax, Z-Pak) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group99 in the study · 6 weeks · 500 mg, on 3 consecutive days of the week during 6 weeks
Overall symptoms improved.
The evidence is very uncertain about the effect of azithromycin (Zithromax, Z-Pak) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
Azithromycin in chronic fatigue syndrome (CFS), an analysis of clinical data. (2006)
- People in the study
- 99 in the study
- Dose
- 500 mg, on 3 consecutive days of the week during 6 weeks
- Outcome
- reported an improvement of symptoms
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
250 to 500 mg at the start
- 2Top dose
Most often 500 mg (2 of 3 studies)
Doses across 3 studies
250 to 500 mg.
Each study’s dose, as printed
- 250 mg, 3 days a week for 3 months From dyspnea to Olympic qualification - A case report as a model for post-acute sequelae of COVID-19. (2025)
- 500 mg, daily Persistent hiccups after acute COVID-19 successfully treated with chlorpromazine: a case report. (2024)
- 500 mg, on 3 consecutive days of the week during 6 weeks Azithromycin in chronic fatigue syndrome (CFS), an analysis of clinical data. (2006)
All papers
- Effect of drug therapies on self-reported chemosensory outcomes after COVID-19.2024 · compared with another group · 714 in the study
Summary
This cross-sectional study interviewed 714 people with self-reported post-COVID-19 taste and/or smell disorders, recruited through advertisements on social networks, a median of 81 days (interquartile range 60–104) after COVID-19 symptom onset. Of these, 437 used at least one medication for COVID-19 and 277 used none; treatment duration was not reported. The main measure was self-reported total recovery of smell and taste, with severity also rated 0–10. Total recovery was reported by 249 (34.9%). The recovery rates of the treated and nontreated groups did not differ significantly. In adjusted models, oral zinc was associated with lower odds of return to normal olfaction or taste capacity (odds ratio 0.24; 95% CI 0.1–0.5; p < 0.001), and nitazoxanide had an odds ratio of 3.30 (95% CI 1.35–8.20; p = 0.009), although the text states findings for nitazoxanide, systemic corticosteroids, and azithromycin did not reach statistical significance after Bonferroni correction. Adverse events were reported in 55 out of 483 (11.4%) medication users; side-effect percentages were 22.4% for chloroquine or hydroxychloroquine, 14.3% for azithromycin, and 13.9% for oral zinc. Withdrawals related to harms were not reported. The paper also reports 437 medication users in the results and 483 in the adverse-event section.
- Retrospektive Analyse der Azithromycin-Therapie bei Post-Covid-Patienten2022 · no comparison group · 45 in the study · 25 started
- Azithromycin in chronic fatigue syndrome (CFS), an analysis of clinical data.2006 · no comparison group · 99 in the study
Summary
This retrospective study examined patient-record responses to azithromycin in CFS at the CFS and Pain Research Center Amsterdam. 99 patients diagnosed according to the Fukuda criteria were treated from April 2000 to August 2005. Azithromycin 500 mg was given on 3 consecutive days of the week during 6 weeks, offered when counseling and L-carnitine were considered insufficient. There was no separate comparison group; responders were compared with non-responders and with plasma acetylcarnitine strata. The patient-rated clinical global impression was scored after a standard interview, alongside questionnaires and plasma carnitines. Of 99 patients, 58 (59%) reported improvement of symptoms, and no patients were worse at the end of treatment. Side effects were minor bowel problems that resolved by dividing the daily dosage. Responders were younger, 34.7 ± 11.5 versus 40.4 ± 12.6 years in the text (Table 1 lists 40.3 (12.7)). Plasma acetylcarnitine was lower in responders, 4.78 ± 1.66 μM versus 5.87 ± 2.55 μM (P = 0.023). Improvement was present in 77% with acetylcarnitine less than 4.1 μM, 58% between 4.1 and 6.5 μM, and 31% higher than 6.5 μM. No differences were reported for MFI-20, 4DSQ, pain VAS or SHAQ.
- Persistent hiccups after acute COVID-19 successfully treated with chlorpromazine: a case report.2024 · case report · 1 in the study
Summary
This case report describes a 27-year-old male black Zambian patient who presented to the emergency department with persistent hiccup in the post-acute COVID-19 period. The report has no comparison group. Chlorpromazine was prescribed at 25 mg three times a day. The patient was also commenced on Azithromycin 500 mg daily, Zinc 20 mg daily and Vitamin C 1000 mg daily. The report does not state a planned treatment duration. It describes hiccup frequency and resolution, recurrence, and symptom-free status. A day after initial presentation, the hiccup was occurring less frequently. On the second day after commencing treatment with chlorpromazine, the hiccups stopped completely, and did not recur during the rest of the recovery period; the hiccups disappeared completely after the fourth dose of chlorpromazine. The patient was reviewed after 2 weeks, 4 weeks and 12 weeks after resolution of hiccups. There was no recurrence of the hiccup, and he remained completely symptom free. Harms and withdrawals were not reported. The authors state that lack of laboratory reagents and lack of access to CT scan and MRI were significant limitations.
- Post-COVID-19 neuropsychiatric manifestations: a suggested therapeutic approach to 'long COVID' with azithromycin.2023 · case report · 3 in the study
Summary
This paper reports a clinical experience of azithromycin in three patients with neurological symptoms associated with long COVID-19. Three patients were enrolled, three started, and three were analysed. The authors describe a suggested therapeutic approach to long COVID. The setting was not reported. Azithromycin was the experimental treatment; dose, route, schedule and duration were not reported, and follow-up was not reported. There was no comparison group, the report was not randomised, and no crossover was reported. The outcome described was a favourable clinical response, and the authors report improvement in the three patients. No p-value, interval or significance words are reported for this response. No side effects, harms, or withdrawals were reported. No patients were reported to worsen or stop treatment. Funding and conflicts of interest were not reported. The authors state that scientific evidence is weak at this time and suggest clinical trials to assess azithromycin alone for long COVID-19.
- From dyspnea to Olympic qualification - A case report as a model for post-acute sequelae of COVID-19.2025 · combination: given with other treatments · 1 in the study
Summary
This case report describes one 24-year-old female professional athlete with post-acute sequelae of COVID-19 (PASC) after a mild SARS-CoV-2 infection. She was diagnosed in the Department of Pneumology at the Bundeswehr Hospital in Ulm in July 2022 and received step-by-step treatment at the same clinic until March 2023. The multimodal therapy concept included azithromycin 250 mg 3 days a week for 3 months; anti-obstructive inhalation therapy with indacaterol/mometasone 125/260 μg, escalated after 6 weeks to glycopyrronium/indacaterol/mometasone 46/136/114 μg; 3 sessions of bronchial thermoplasty; and myoreflex therapy every 14 days. There was no comparison group; outcomes were compared before and after treatment. Lung function and spiroergometry were measured. After 3 months, significant improvements were registered. A functional follow-up 3 months later confirmed significant clinical and functional improvements. Table 1 reported FVC 91 to 102, FEV1 74 to 99, Tiffeneau-Index 68 to 83, MEF50 51 to 92, TLC 131 to 110, RV/TLC 163 to 93, DLCO 107 to 105, KCO 106 to 107, power 130 to 205 watts, VO2max 81 to 108, and oxygen pulse 107 to 126. The authors also reported complete remission of pulmonary PASC within 35 weeks and a successful qualification for the Paris Olympic summer games in June 2024. Harms and withdrawals were not reported. Limitations were not reported.
- Successful Diagnosis and Treatment of Borrelia miyamotoi in a Patient with Joint and Muscle Pains, ME/CFS, and Cognitive Dysfunction following Tick Bites: A Case Report2024 · combination: given with other treatments · 1 in the study
Summary
This is a case study of one patient: a 46-year-old female with ME/CFS, joint and muscle pain, chronic fatigue, and cognitive impairment after tick bites in Europe. The paper reports one enrolled, started, and analysed patient. The paper reports that phb-PCR identified Borrelia miyamotoi after standard diagnostic tests returned negative results. The patient was treated with intravenous ceftriaxone, oral azithromycin, and intravenous vitamin and mineral therapy; the duration of treatment was not reported. There was no comparison group, and the study was not randomised. The paper reports 'significant improvement in symptoms, including reduced pain, improved cognitive function, and decreased fatigue.' No time point for this improvement was reported. Harms were not reported. Withdrawals were not reported. No difference, worsening, or stopping was reported. Follow-up duration and limitations were not reported. The authors conclude: 'This case emphasises the importance of direct diagnostic methods like phb-PCR for accurately identifying BMD, especially when conventional serological tests fail.'
- Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis.2013 · combination: given with other treatments
- Comparative efficacy and safety of pharmacological interventions for the treatment of long COVID in adults: a systematic review and network meta-analysis2026 · systematic review
Summary
A systematic review and network meta-analysis examined pharmacological treatments for long COVID in adults, including trials on COVID-19 symptoms related to long COVID. Records were searched in PubMed/MEDLINE, Cochrane Library, Embase, CINAHL, PsycINFO and Web of Science from the beginning of 2020 to October 31, 2022. The review included 129 studies: 109 RCTs and 20 observational studies. The number of patients enrolled or analysed in the review was not recorded in the extracted data, and treatment duration or follow-up was not reported. Treatments included ivermectin mucoadhesive nanosuspension nasal spray (Aref 2021, 114 patients; Aref 2022, 96 patients), oxaloacetate, anticoagulants, hyperbaric oxygen and others; comparisons were against control (placebo/SOC) or other interventions. Outcomes included mortality, hospital admission, ICU admission, mechanical ventilation, symptom recovery, adverse events, serious adverse events, major bleeding, olfactory scores and thrombotic events. The extracted results contained no between-group result. Recorded harms included higher adverse-event odds with high-dose zinc (OR=21.87, 95%CI [1.25, 383.45]), high-dose vitamin C (OR=56.11, 95%CI [3.26, 966.29]) and tocilizumab (OR=9.64, 95%CI [2.76, 33.75]); major bleeding with treatment-dose anticoagulants (OR=1.86, 95%CI [1.19, 2.89]) and increased ICU admission with propolis. Stopping or dose change was not reported. The authors stated that some results came from a single study or studies with high RoB.
- Risk factors and preventive interventions for post Covid-19 condition: systematic review2022 · systematic review
Summary
Why: to see whether treatments given during acute or early post-acute Covid-19 prevent post Covid-19 condition (symptoms ≥12 weeks after onset). Who: a systematic review of 31 studies; the searches were run on 28 July 2021 for the intervention question. Several preventive-intervention studies were retrospective controlled cohorts, and most were in hospitalized patients. What was given and compared: corticosteroids, antibiotics, hydroxychloroquine, therapeutic anticoagulation, zinc, intravenous immunoglobulin, oseltamivir, ganciclovir, human umbilical cord mesenchymal stem cells (12 vs 29), an ayurvedic formulation (30 vs 30), Chinese medicine (64 vs 32), telerehabilitation (14 vs 13), cognitive-motor therapy (42), photobiomodulation (5 vs 5), and screening with referrals. Found: certainty was very low throughout. Examples: with stem cells, adverse events were 0 and serious adverse events 0; with the ayurvedic formulation, fatigue was 1 (5%) vs 6 (26.1%); with photobiomodulation, respiratory symptoms were 0/5 (0%) vs 4/5 (80%); with telerehabilitation, adverse events were none reported; with Chinese medicine there was no significant difference in the improvement rates of symptoms, including fatigue, between the two groups (p > .05); antibiotic use was associated with salivary gland ectasia, aOR 8.34 (95% CI, 1.47–158.19).
- Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
Summary
This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.